ASPIRA

Aspira Pathlab & Diagnostics Ltd.

BSE: 540788

Sector: Healthcare

Industry Group: Healthcare Services

Industry: Healthcare Service Provider

120.40+5.7 (+4.97%)

14 Oct, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

42.2 / 100

Value Score

10.1 / 100

Price Momentum Score

87.7 / 100

QVM Score

38.8 / 100

Key Metrics

Market Cap

123.93

P/E (TTM)

P/B

10.13

P/S (TTM)

4.78

EV/EBITDA

126.90

CAPE (5Y)

364.23

ROE (TTM)

0.42

ROCE (TTM)

-0.49

ROA (TTM)

0.29

Avg 3Y ROE

-1.60

Earnings 3Y CAGR

2.81

Sales 3Y CAGR

22.49

Sales 5Y CAGR

5.77

Debt/Equity

0.27

Consensus TP

Strong Buy %

Promoter Holding

46.58

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Aspira Pathlab & Diagnostics Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 87.7 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

87.7 / 100

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.27 as on 30 Jun 2026 and Debt to Equity increased marginally by 0.01 in the last 1 year

What is Debt to Equity?

Company's earnings are of high quality

Earnings quality score of 86.8 indicates that the company's earnings are of high quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

86.8 / 100

Negative

Stock is fairly expensive with negative EPS on a trailing 12-month basis

Earnings yield of 0.04% indicates that the stock is very expensive and has a negative EPS on a trailing 12-month basis

What is Earnings yield (E/P)?

Low and declining ROE

The company reported low ROE of 0.42% for 12-month ended 30 Jun 2026 and ROE declined by -1770 bps from 1 year ago

What is ROE (FY)?

Low and declining operating margin

The company reported low operating margin of -2.29% for 12-month ended 30 Jun 2026 and operating margin declined by -1340 bps from 1 year ago

What is Operating profit margin?

Low EPS growth and lower than median growth of industry

The company delivered moderate EPS growth of -119.25% for 12-month ended 30 Jun 2026 and the growth was 140.73 percentage points lower than median growth of industry

What is EPS growth (1Y)?

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Moderate revenue growth and in line with median growth of industry

The company delivered moderate revenue growth of 14.57% for 12-month ended 30 Jun 2026 and the growth was 0.0 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 14.57

Value 14.57

-93.87133.74

Financial Snapshot

See detailed analysis

Multi-year trends for Aspira Pathlab & Diagnostics Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Aspira Pathlab & Diagnostics Ltd. Shareholding Pattern

Quarterly breakdown of Aspira Pathlab & Diagnostics Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	40.15	40.15	40.15	40.15	36.25	36.25	36.25	36.25	36.25	36.19	34.55	19.48	19.47	19.37	18.90	18.90	18.72	18.72	18.55	18.55	18.39	18.39	18.39	18.39	18.39	46.58
Indian Promoter	40.15	40.15	40.15	40.15	36.25	36.25	36.25	36.25	36.25	36.19	34.55	19.48	19.47	19.37	18.90	18.90	18.72	18.72	18.55	18.55	18.39	18.39	18.39	18.39	18.39	46.58
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	-	-	-	-	-	-	-	-	-	-	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Mutual Funds / UTI	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FI/Bank/Insurance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Non-Institution	59.85	59.85	59.85	59.85	63.75	63.75	63.75	63.75	63.75	63.81	65.45	80.52	80.53	80.63	81.10	81.10	81.28	81.28	81.45	81.45	81.61	81.61	81.61	81.61	81.61	53.42
Bodies Corporate	11.85	11.85	11.85	11.85	20.41	20.41	20.42	20.42	19.03	14.83	11.83	12.35	11.56	11.35	11.34	11.58	7.17	2.99	0.24	1.22	1.17	1.16	0.21	0.19	0.20	0.19
Others (incl. Retail) No. of shareholders	48.00 522	48.00 524	48.00 523	48.00 523	43.34 522	43.34 522	43.33 702	43.33 838	44.72 855	48.98 942	53.62 1,127	68.17 1,281	68.97 1,285	69.28 1,357	69.76 1,394	69.52 1,336	74.11 1,499	78.29 1,682	81.21 1,692	80.23 1,574	80.44 1,725	80.45 1,755	81.40 1,744	81.42 1,773	81.41 1,757	53.23 1,605

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Aspira Pathlab & Diagnostics Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Jay Arvind Bhanushali Promoters Immediate Relative	June-2025	Market Purchase (Acquisition) 2nd Jun 2025	2.26 %	₹ 51.55	150.00	₹ 7.73 k
Jay Arvind Bhanushali Promoters Immediate Relative	May-2025	Market Purchase (Acquisition) 28th May 2025	2.22 %	₹ 54.50	250.00	₹ 13.63 k
Jay Arvind Bhanushali Promoters Immediate Relative	May-2025	Market Purchase (Acquisition) 28th May 2025	2.22 %	₹ 55.00	150.00	₹ 8.25 k
Jay Arvind Bhanushali Promoters Immediate Relative	May-2025	Market Purchase (Acquisition) 28th May 2025	2.23 %	₹ 54.00	3.25 k	₹ 1.75 lac
Jay Arvind Bhanushali Promoters Immediate Relative	May-2025	Market Purchase (Acquisition) 28th May 2025	2.23 %	₹ 54.00	479.00	₹ 25.87 k
Paresh Bhanji Bhanushali Promoter	March-2025	Market Sale (Disposal) 25th Mar 2025	0.43 %	₹ 107.00	1.00	₹ 107.00
Paresh Bhanji Bhanushali Promoter	March-2025	Market Sale (Disposal) 25th Mar 2025	0.58 %	₹ 101.70	16.00 k	₹ 16.27 lac
Paresh Bhanji Bhanushali Promoter	August-2024	Market Sale (Disposal) 19th Aug 2024	0.76 %	₹ 30.30	18.00 k	₹ 5.45 lac
Shraddha Bhanushali Directors Immediate Relative	June-2024	Market Purchase (Acquisition) 29th Jun 2024	1.14 %	₹ 30.00	32.50 k	₹ 9.75 lac
Nikunj Velji Mange Director	June-2024	Market Purchase (Acquisition) 29th Jun 2024	1.82 %	₹ 29.97	32.50 k	₹ 9.74 lac

…

No corporate action data available.

Company Profile

Overview of Aspira Pathlab & Diagnostics Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Aspira Pathlab & Diagnostics Limited is an India-based company, which is engaged in the business of running, owning, managing, and administering Diagnostics Centers. The principal activities of the Company consist of pathology investigation services, radiology investigation services and other relate...

Incorporated on

03 Jul 1973

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

168

IPO date

05 Dec 2017

Free Float

11,36,130

Website

https://www.aspiradiagnostics.com/

Phone no.

+912271975756

Address

Flat No.2 R. D. Shah Bldg,, Shraddhanand Road,Opp, Ghatkopar Railway Station, Ghatkopar (W),, MUMBAI, 400086, India

Frequently Asked Questions

What is the current share price of Aspira Pathlab & Diagnostics Ltd.?

The current share price of Aspira Pathlab & Diagnostics Ltd. is ₹ 120.40 as of 14 Oct 2026.

What is the market capitalisation of Aspira Pathlab & Diagnostics Ltd.?

The market capitalisation of Aspira Pathlab & Diagnostics Ltd. stands at ₹ 123.93 Cr.

What is the PE ratio of Aspira Pathlab & Diagnostics Ltd.?

The Price-to-Earnings (PE) ratio of Aspira Pathlab & Diagnostics Ltd. is - as of the latest trailing twelve months data.

What is the ROE and ROCE of Aspira Pathlab & Diagnostics Ltd.?

Aspira Pathlab & Diagnostics Ltd. has a Return on Equity (ROE) of 0.42% and a Return on Capital Employed (ROCE) of -0.49% as per the latest financial reports.

What is the 52-week high and low of Aspira Pathlab & Diagnostics Ltd.?

The 52-week high of Aspira Pathlab & Diagnostics Ltd. is - and the 52-week low is -.

What is the dividend yield of Aspira Pathlab & Diagnostics Ltd.?

The dividend yield of Aspira Pathlab & Diagnostics Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Aspira Pathlab & Diagnostics Ltd.?

Foreign Institutional Investors (FII) hold 0.00%, Domestic Institutional Investors (DII) hold 0.00% and retail/public investors hold 53.23% of Aspira Pathlab & Diagnostics Ltd. shares.

What sector does Aspira Pathlab & Diagnostics Ltd. belong to?

Aspira Pathlab & Diagnostics Ltd. operates in the Healthcare sector.

What is the beta of Aspira Pathlab & Diagnostics Ltd.?

The beta of Aspira Pathlab & Diagnostics Ltd. is -0.11, indicating its price volatility relative to the broader market. Over the past 1 year, Aspira Pathlab & Diagnostics Ltd. has delivered an absolute return of 84.07%.

What is the RSI of Aspira Pathlab & Diagnostics Ltd.?

The 14-day Relative Strength Index (RSI) of Aspira Pathlab & Diagnostics Ltd. is 54.09, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Aspira Pathlab & Diagnostics Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Aspira Pathlab & Diagnostics Ltd. Shareholding Pattern

Bulk, Block and Insider Trades

Company Profile

Frequently Asked Questions

Company Profile

Stock Analysis